FIELD: organic chemistry, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to new cytotoxic macrolide compound of the formula (I) wherein X represents lower alkyl; R1 and R2 represent hydrogen atom or lower alkyl; R3a represents hydrogen atom; R3b represents compounds of the formula (II) or (III) or R3a and R3b in common represent oxygen atom; R4 represents hydrogen atom, hydroxy-group, lower alkoxy-group and so on; R5 represents hydrogen atom, carbamoyl and so on; R6a represents hydrogen atom; R6b represents hydroxy-group either R6a and R6b in common represent oxygen atom; R7 represents hydrogen atom and so on; R8 represents lower alkoxy- group and so on; Y1 represents hydrogen atom or methyl; Y2 represents hydrogen atom or Y1 and Y2 in common represent double bond being in definitions of groups of the formula (I) lower alkyl and lower alkyl fragment of lower alkanoyl or lower alkoxy-group means linear or branched alkyl group comprising 1-6 carbon atoms, such as methyl, ethyl and so on. Invention relates to method for treatment of mammals damaged with malignant tumor sensitive to compound of the formula (I) and involving administration to the damaged individual therapeutically effective dose of indicated compound or its pharmaceutical composition. Invention relates to pharmaceutical preparation eliciting antitumor effect containing compound of the formula (I) as an active component and a carrier. Invention relates to method for preparing compound of the formula (I) that involves treatment of the known Kabiramides taken among Kabiramide B or C with acid, respectively, in suitable solvent. Invention provides preparing new compound eliciting an antitumor effect. EFFECT: improved preparing method, valuable medicinal properties of macrolides. 10 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
ALKALOIDS, METHOD FOR THEIR PREPARING, METHOD FOR TREATMENT, PHARMACEUTICAL COMPOSITION | 1998 |
|
RU2221800C2 |
OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL FOR TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2815636C1 |
OPTIONALLY CONDENSED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE DERIVATIVES SUITABLE FOR TREATING INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | 2015 |
|
RU2719422C2 |
NEUROACTIVE STEROIDS AND METHODS OF THEIR USE | 2014 |
|
RU2808166C2 |
NEUROACTIVE STEROIDS AND METHODS FOR USE THEREOF | 2014 |
|
RU2684103C2 |
NEUROACTIVE STEROIDS, COMPOSITIONS AND THEIR USE | 2012 |
|
RU2808165C2 |
CYCLOPROPYLAMIDE DERIVATIVES AS N-HISTAMINE RECEPTOR MODULATORS | 2007 |
|
RU2449989C2 |
NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF | 2012 |
|
RU2665571C2 |
PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION ELICITING ANTAGONISTIC EFFECT TO HUMAN mGluR | 1998 |
|
RU2203889C2 |
Authors
Dates
2003-11-27—Published
1999-01-27—Filed